Small Lymphocytic Lymphoma

Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

16 drugs in development·8 companies·33 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
Jaypirca	ELI LILLY & Co (LLY)
Jaypirca®	ELI LILLY & Co (LLY)
venetoclax	DR REDDYS LABORATORIES LTD (RDY)

Phase 3(8)

Drug	Company
Bendamustine	ENANTA PHARMACEUTICALS INC (ENTA)
BGB-16673	ENANTA PHARMACEUTICALS INC (ENTA)
BGB-16673	Merus N.V. (MRUS)
Idelalisib	ENANTA PHARMACEUTICALS INC (ENTA)
Obinutuzumab	ASTRAZENECA PLC (AZN)
Sonrotoclax	ENANTA PHARMACEUTICALS INC (ENTA)
Surovatamig	ASTRAZENECA PLC (AZN)
Venetoclax	ASTRAZENECA PLC (AZN)

Phase 2(4)

Drug	Company
ALLO-501A	Allogene Therapeutics, Inc. (ALLO)
ALLO-647	Allogene Therapeutics, Inc. (ALLO)
bruton's tyrosine kinase inhibitor	GH Research PLC (GHRS)
dzd8586	NYMOX PHARMACEUTICAL CORP (NYMXF)

Unknown(1)

Drug	Company
b-cell lymphoma 2 protein inhibitor	GH Research PLC (GHRS)

BioSniper tracks 16 drugs in development for Small Lymphocytic Lymphoma across 8 companies.

There are 33 clinical trials targeting Small Lymphocytic Lymphoma tracked by BioSniper.

The estimated prevalence of Small Lymphocytic Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.